These novel therapies , Retatrutide, represent a groundbreaking advancement in managing obesity and potentially related ailments . They are categorized as GLP-1 receptor agonists , meaning these https://steveqncn268365.newbigblog.com/48276399/semaglutide-a-deep-dive-into-glp-1-agents